{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:59:19Z","timestamp":1790852359709,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1007\/bf03187328","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T20:11:18Z","timestamp":1276632678000},"page":"256-263","source":"Crossref","is-referenced-by-count":12,"title":["Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers"],"prefix":"10.1007","volume":"6","author":[{"given":"Shazza","family":"Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Revell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF03187328_CR1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","volume":"74","author":"ZN Oltvai","year":"1993","unstructured":"Oltvai ZN, Milliman CL, Korsmeyer SJ:Bcl2 heterodinerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Structure-function analysis of Blc2 protein. Cell 74:609\u2013619, 1993.","journal-title":"Cell"},{"key":"BF03187328_CR2","doi-asserted-by":"crossref","first-page":"11962","DOI":"10.1074\/jbc.270.20.11962","volume":"270","author":"M Hanada","year":"1995","unstructured":"Hanada M, Aime-Sempe C, Sato T, et al: Identification of conserved domains important for homodiverization with Bcl2 and heterodiverization with Bax. J Biol Chem 270:11962\u201311969, 1995.","journal-title":"J Biol Chem"},{"key":"BF03187328_CR3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.2910600622","volume":"60","author":"RC Bargou","year":"1995","unstructured":"Bargou RC, Daniel PT, Mapara MY: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis, Int J Cancer 60:854\u2013859, 1995.","journal-title":"Int J Cancer"},{"key":"BF03187328_CR4","first-page":"327","volume":"46","author":"SJ Korsmeyer","year":"1993","unstructured":"Korsmeyer SJ, Shutter JR, Veis DJ, et al: Bcl-2\/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 46:327\u2013332, 1993.","journal-title":"Semin Cancer Biol"},{"key":"BF03187328_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90513-8","volume":"80","author":"T Miyashita","year":"1995","unstructured":"Miyashita T, Reed JC: Tumour suppressor p53 is a direct transcriptonal activator of the human Bax gene. Cell 80:293\u2013299, 1995.","journal-title":"Cell"},{"key":"BF03187328_CR6","first-page":"2499","volume":"17","author":"N Kapranos","year":"1997","unstructured":"Kapranos N, Karaiosifidi H, Valavanis C, et al: Prognostic significance of apoptosis relate1.2d proteins Bcl-2 and Bax in node-negative breast cancer patients, Anticancer Research 17:2499\u2013505, 1997.","journal-title":"Anticancer Research"},{"key":"BF03187328_CR7","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the Bcl2 gene in human folicular lymphoma. Science 228:1440\u20131443, 1985.","journal-title":"Science"},{"key":"BF03187328_CR8","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1073\/pnas.88.16.6961","volume":"88","author":"DM Hockenberg","year":"1991","unstructured":"Hockenberg DM, Zutter M, Hickey W, et al: Bcl2 protein is topgraphically restricted in tissues characterised by apoptotic cell death. Proc Natl Acad Sci 88:6961\u20136965, 1991.","journal-title":"Proc Natl Acad Sci"},{"key":"BF03187328_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0960-9776(93)90055-K","volume":"2","author":"B Nathan","year":"1993","unstructured":"Nathan B, Anbazhagan R, Dyer M, et al: Expression of Bcl2 like immunoreactivity in the normal breast and in breast cancer. The Breast 2:134\u2013137, 1993.","journal-title":"The Breast"},{"key":"BF03187328_CR10","first-page":"47","volume":"424","author":"C Doglioni","year":"1994","unstructured":"Doglioni C, DeiTos AP, Laurino L, et al: The prevalence of Bcl2 immunoreactivity in breast carcinomas and its clinicopatholigical correlates, with particular reference to oestrogen receptor status. Virchous Arch 424:47\u201351, 1994.","journal-title":"Virchous Arch"},{"key":"BF03187328_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ijc.2910590508","volume":"59","author":"JM Gee","year":"1994","unstructured":"Gee JM, Robertson JF, Ellis IO:Immunocytochemical localization of Bcl2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619\u2013628, 1994","journal-title":"Int J Cancer"},{"key":"BF03187328_CR12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/86.7.499","volume":"86","author":"R Silvestrini","year":"1994","unstructured":"Silvestrini R, Veneroni S, Daidone MG: The Bcl2 protein: a prognostic indicator strongly related to p53 protein in lymphnode negative breast cancer patients. J Natl Cancer Inst 86:499\u2013504, 1994.","journal-title":"J Natl Cancer Inst"},{"key":"BF03187328_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.1711770109","volume":"177","author":"P Lipponen","year":"1995","unstructured":"Lipponen P, Pietilainen T, Kosma VM, et al: Apoptosis suppressing protein Bcl2 is expressed in well differentiated breast carcinomas with favourable prognosis. J Pathol 177:49\u201355, 1995.","journal-title":"J Pathol"},{"key":"BF03187328_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP: p53, guardian of the genome. Nature 358:15\u201316, 1992.","journal-title":"Nature"},{"key":"BF03187328_CR15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/351453a0","volume":"351","author":"AL Levine","year":"1991","unstructured":"Levine AL, Momand J, Finlay CA: The p53 tumour suppression gene. Nature 351:453\u2013456, 1991.","journal-title":"Nature"},{"key":"BF03187328_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollestein","year":"1991","unstructured":"Hollestein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancer. Science 253: 49\u201353, 1991","journal-title":"Science"},{"key":"BF03187328_CR17","first-page":"2095","volume":"54","author":"S Haider","year":"1994","unstructured":"Haider S, Negrini M, Moune M, et al: Down regulation of Bcl2 by p53 in breast cancer cells. Cancer Res. 54:2095\u20132097, 1994","journal-title":"Cancer Res."},{"key":"BF03187328_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-9896(199605)179:1<10::AID-PATH540>3.0.CO;2-1","volume":"179","author":"L Kaklamanis","year":"1996","unstructured":"Kaklamanis L, Savage A, Mortensen N, et al: Early expression of Bcl2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179:10\u201314, 1996.","journal-title":"J Pathol"},{"key":"BF03187328_CR19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jcp.49.5.395","volume":"49","author":"H Shiina","year":"1996","unstructured":"Shiina H, Igawa M, Urakami S, et al: Immunohistochemical analysis of Bcl2 expression in transitional cell carcinoma of the bladder. J Clin Palliol. 49:395\u2013399, 1996","journal-title":"J Clin Palliol."},{"key":"BF03187328_CR20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jnci\/84.11.845","volume":"84","author":"AD Thor","year":"1992","unstructured":"Thor AD, Moore DH II,Edgerton SM, et al: Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancers. J. Natl Cancer Inst 84:845\u2013855, 1992.","journal-title":"J. Natl Cancer Inst"},{"key":"BF03187328_CR21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with exclusive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132\u20131139, 1985.","journal-title":"Science"},{"key":"BF03187328_CR22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ajcp\/96.2.243","volume":"96","author":"RA Wolber","year":"1991","unstructured":"Wolber RA, Dupuis, BA, Wick MR: Expression of cerbB2 oncoprotein in mammary and extramammary Pagets\u2019 disease. Am J Clin Pathol 96:243\u2013247, 1991.","journal-title":"Am J Clin Pathol"},{"key":"BF03187328_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/319230a0","volume":"319","author":"T Yamamoto","year":"1986","unstructured":"Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human cerbB2 gene to epidermal growth factor receptor. Nature 319:230\u2013234, 1986.","journal-title":"Nature"},{"key":"BF03187328_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcb.240531125","volume":"17","author":"DC Allred","year":"1993","unstructured":"Allred DC, O\u2019Connell P, Fugua AW: Biomarkers in early breast neoplasia. J. Cell Biochem 17:125\u2013131, 1993.","journal-title":"J. Cell Biochem"},{"key":"BF03187328_CR25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcb.240531126","volume":"17","author":"DM Barnes","year":"1993","unstructured":"Barnes DM: cerbB2 amplification in mammary carcinoma. J Cell Biochem 17:132\u2013138, 1993.","journal-title":"J Cell Biochem"},{"key":"BF03187328_CR26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/bjc.1991.78","volume":"63","author":"TJ Perren","year":"1991","unstructured":"Perren TJ: cErbB2 oncogene as a prognostic marker in breast cancer. Br J. Cancer 63:328\u2013332, 1991.","journal-title":"Br J. Cancer"},{"key":"BF03187328_CR27","first-page":"163","volume-title":"a molecular approach. Breast Cancer","author":"AM Thompson","year":"1994","unstructured":"Thompson AM:Lemoine N, Neoptolemos J, Cooke T, eds. Cancer, a molecular approach. Breast Cancer. Oxford: Blackwells 163\u2013183, 1994"},{"key":"BF03187328_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu encogene. Science 235:177\u2013182, 1987.","journal-title":"Science"},{"key":"BF03187328_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","volume":"31","author":"J Gerdes","year":"1983","unstructured":"Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13\u201320, 1983","journal-title":"Int J Cancer"},{"key":"BF03187328_CR30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0959-8049(05)80215-1","volume":"29A","author":"RL Nicholson","year":"1993","unstructured":"Nicholson RL, McClelland RA, Finlay P, et al: Relationship between EGFR, cerbB2 protein expression and ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A:1018\u20131023, 1993","journal-title":"Eur J Cancer"},{"key":"BF03187328_CR31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/bjc.1989.200","volume":"59","author":"Walker KJ BouzubarN","year":"1989","unstructured":"BouzubarN, Walker KJ, Griffiths K, et al: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943\u2013947, 1989.","journal-title":"Br J Cancer"},{"key":"BF03187328_CR32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/bjc.1995.30","volume":"71","author":"SE Pinder","year":"1995","unstructured":"Pinder SE, Wencyk P, Sibbering DM, et al: Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis; associations with other prognostic factors and survival. Br J Cancer 71:146\u2013149, 1995.","journal-title":"Br J Cancer"},{"key":"BF03187328_CR33","first-page":"224","volume":"18","author":"AP Locker","year":"1992","unstructured":"Locker AP, Birrell K, Bell JA, et al: Ki67 immunoreactivity in breast carcinoma: relationship to prognostic variables and short term survival. Eur J Surg Oncol 1992; 18:224\u2013229, 1992.","journal-title":"Eur J Surg Oncol 1992"},{"key":"BF03187328_CR34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0277-5379(91)90145-4","volume":"27","author":"RI Nicholson","year":"1991","unstructured":"Nicholson RI, Bouzubar N, Walker KJ, et al: Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27:908\u2013913, 1991","journal-title":"Eur J Cancer"},{"key":"BF03187328_CR35","first-page":"6126","volume":"47","author":"SM Thorpe","year":"1987","unstructured":"Thorpe SM, Rose C, Rasmussen BB, et al: Prognostic value of steroid hormone receptor multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47:6126\u20136133, 1987.","journal-title":"Cancer Res"},{"key":"BF03187328_CR36","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM197812142992403","volume":"299","author":"DT Kiang","year":"1978","unstructured":"Kiang DT, Frenning DH, Goldman AL, et al: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330\u20131333, 1978.","journal-title":"N Engl J Med"},{"key":"BF03187328_CR37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0277-5379(90)90013-J","volume":"26","author":"J Anderson","year":"1990","unstructured":"Anderson J, Thorp SM, King WJ, et al:The prognostic value of immunohistochemical oestrogen receptor analysis in paraffin embedded and frozen sections versus that of steroid binding assays. Eur J Cancer 26:442\u2013449, 1990.","journal-title":"Eur J Cancer"},{"key":"BF03187328_CR38","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1997.15.5.1916","volume":"15","author":"RM Elledge","year":"1997","unstructured":"Elledge RM, Green S, Howes L, et al: Bcl2, p53 and response to lamonifen in oestrogen receptor positive metastatic breast cancer: a southwest oncology group study. J Clin Oncol 15:1916\u20131922, 1997.","journal-title":"J Clin Oncol"},{"key":"BF03187328_CR39","first-page":"167","volume":"11","author":"R Holland","year":"1994","unstructured":"Holland R, Peterse JL, Millis RR, et al: Ductal carcinoma in situ: A proposal for a new classification. Seminars in Diagnostic Pathology. 11:167\u2013180, 1994.","journal-title":"Seminars in Diagnostic Pathology"},{"key":"BF03187328_CR40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology; 19:403\u2013410, 1991","journal-title":"Histopathology"},{"key":"BF03187328_CR41","first-page":"82","volume":"17","author":"MO Vilain","year":"1997","unstructured":"Vilain MO, Delobelle-Deroide A, Bloget F, et al: Immunohistochemical detection of oestrogen and progesterone receptors in formation fixed, paraffin embedded tissues after microwave treatment. Comparison with biochemical assay in a series of 123 breast carcinomas with determination of the positivity cut off. Annales de Pathologie. 17:82\u201388, 1997.","journal-title":"Annales de Pathologie"},{"key":"BF03187328_CR42","first-page":"1323","volume":"145","author":"S Krajewski","year":"1994","unstructured":"Krajewski S, Krajewska M, Shabaik A, et al: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl2. Am J Pathol; 145:1323\u20131336, 1994.","journal-title":"Am J Pathol"},{"key":"BF03187328_CR43","volume-title":"International Histological Classification of Tumours","author":"World Health Organisation","year":"1981","unstructured":"World Health Organisation, (1981) Histological typing of breast tumours. International Histological Classification of Tumours, 2nd Edition World Health Organisation, Geneva.","edition":"2nd Edition"},{"key":"BF03187328_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1083\/jcb.124.1.1","volume":"124","author":"JC Reed","year":"1994","unstructured":"Reed JC: Bcl2 and the regulation of programmed cell death. J Cell Biol 124:1\u20136, 1994.","journal-title":"J Cell Biol"},{"key":"BF03187328_CR45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1242\/jcs.1994.Supplement_18.7","volume":"18","author":"DM Hockenberg","year":"1994","unstructured":"Hockenberg DM: Bcl2 in cancer, development and apoptosis. J Cell Sci 18:51\u201355, 1994.","journal-title":"J Cell Sci"},{"key":"BF03187328_CR46","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J","volume":"73","author":"JF Kerr","year":"1994","unstructured":"Kerr JF, Winterford CM, Harmon BV: Apoptosis \u2014 its significance in cancer and cancer therapy. Cancer 73:2013\u20132026, 1994.","journal-title":"Cancer"},{"key":"BF03187328_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.10.1.1","volume":"10","author":"E White","year":"1996","unstructured":"White E: Life, death and the pursuit of apoptosis. A review. Genes and Development 10:1\u201315, 1996.","journal-title":"A review. Genes and Development"},{"key":"BF03187328_CR48","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386","volume":"88","author":"E Yang","year":"1996","unstructured":"Yang E, Korsmeyer SK: Molecular thanatopsis: a discourse on the Bcl2 family and cell death. Blood 88:386\u2013401, 1996.","journal-title":"Blood"},{"key":"BF03187328_CR49","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.7878464","volume":"267","author":"CB Thompson","year":"1995","unstructured":"Thompson CB: Apoptosis in the pathogensis and the treatment of disease. Science 267:1456\u20131462, 1995.","journal-title":"Science"},{"key":"BF03187328_CR50","first-page":"107","volume":"200","author":"LH Broise","year":"1995","unstructured":"Broise LH, Gottschalk AR, Quinfans J, Thompson CB:Bcl2 and Bcl2 related proteins in apoptosis regulation. Curr Top Microbiol Immunol 200:107\u2013121, 1995.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BF03187328_CR51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/scbi.1995.0005","volume":"6","author":"RW Craig","year":"1995","unstructured":"Craig RW: The Bcl2 gene family. Semin Cancer Biol 6:35\u201343, 1995.","journal-title":"Semin Cancer Biol"},{"key":"BF03187328_CR52","first-page":"4471","volume":"55","author":"S Krajewski","year":"1995","unstructured":"Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471\u20134478, 1995","journal-title":"Cancer Res"},{"key":"BF03187328_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01008011","volume":"430","author":"N Kapucuoglu","year":"1997","unstructured":"Kapucuoglu N, Losi L, Eusebi V: Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch 430:17\u201322, 1997","journal-title":"Virchows Arch"},{"key":"BF03187328_CR54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1440-1827.1999.00942.x","volume":"49","author":"Q Yang","year":"1999","unstructured":"Yang Q, Sakurai T, Jing X, et al: Expression of Bcl2, but not Bax, correlates with estrogen receptor status and tumour proliferation in invasive breast carcinoma, Pathology International, 49;775\u2013780, 1999.","journal-title":"Pathology International"},{"key":"BF03187328_CR55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F","volume":"87","author":"P Rochaix","year":"1999","unstructured":"Rochaix P, Krajewski S, Reed JC, et al: In vivo patterns of Bcl2 family protein expression in breast carcinoma in relation to apoptosis. J Pathol 87:410\u2013415, 1999.","journal-title":"J Pathol"},{"key":"BF03187328_CR56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/bjc.1996.319","volume":"74","author":"Slooten HJ Van","year":"1996","unstructured":"Van Slooten HJ, Clahsen PC, Van Dierendonck JH: Expression of Bcl2 in node negative breast cancer is associated with various prognostic factors, but does not predict response to one course of peri-operative chemotherapy, Br J Cancer 74:78\u201385, 1996.","journal-title":"Br J Cancer"},{"key":"BF03187328_CR57","first-page":"1191","volume":"145","author":"H Joensuu","year":"1994","unstructured":"Joensuu H, Pylkkanen L, Loikkanen S: Bcl2 protein expression and long term survival in breast cancer, Amer J Pathol 145:1191\u20131198, 1994.","journal-title":"Amer J Pathol"},{"key":"BF03187328_CR58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO;2-#","volume":"77","author":"KP Siziopikou","year":"1996","unstructured":"Siziopikou KP, Prioleau JE, Harris JR, et al: Bcl2 expression in the spectrum of pre-invasive breast lesions. Cancer 77:499\u2013506, 1996","journal-title":"Cancer"},{"key":"BF03187328_CR59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2559.1998.00505.x","volume":"3","author":"CM Quinn","year":"1998","unstructured":"Quinn CM, Ostrowski JL, Harkins L, et al: Loss of Bcl2 expression in DCIS of the breast relates to poor histological differentiation and to expression of p53 and cerbB2 proteins. Histopathology 3:531\u2013536, 1998.","journal-title":"Histopathology"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03187328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03187328\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03187328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T20:00:38Z","timestamp":1591387238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03187328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["BF03187328"],"URL":"https:\/\/doi.org\/10.1007\/bf03187328","relation":{},"ISSN":["1219-4956"],"issn-type":[{"value":"1219-4956","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}